Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 7Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 1Glioblastoma 1Adenocarcinoma 1

Interventions

pembrolizumab 241Carboplatin 170Injections 139Paclitaxel 122Gemcitabine 118Bevacizumab 117Cisplatin 108Pemetrexed 80Docetaxel 80Cyclophosphamide 74Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 60Nivolumab 55Cetuximab 53fludarabine 52Leucovorin 51130-nm albumin-bound paclitaxel 50Dexamethasone 46Rituximab 41atezolizumab 38venetoclax 35toripalimab 35Drug Therapy 35enzalutamide 32Prednisone 32Letrozole 32Irinotecan 32durvalumab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Valacyclovir × Clear all
NCT07346144 2026-05-04

ADePT

Trogenix ltd

Phase 1/2 Recruiting
68 enrolled
CNS

Glioblastoma

NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡